As of 2026-04-13, the Intrinsic Value of Rocket Pharmaceuticals Inc (RCKT) is -7.78 USD. This RCKT valuation is based on the model Peter Lynch Fair Value. With the current market price of 3.49 USD, the upside of Rocket Pharmaceuticals Inc is -322.86%.
Based on its market price of 3.49 USD and our intrinsic valuation, Rocket Pharmaceuticals Inc (RCKT) is overvalued by 322.86%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -7.78 - -7.78 | -7.78 | -322.86% |
| P/E | (29.06) - (33.41) | (31.89) | -1013.7% |
| DDM - Stable | (23.46) - (365.54) | (194.50) | -5673.1% |
| DDM - Multi | (0.57) - (6.80) | (1.05) | -130.0% |
| Market Cap (mil) | 500.58 |
| Beta | 1.70 |
| Outstanding shares (mil) | 143.43 |
| Enterprise Value (mil) | 444.30 |
| Market risk premium | 4.60% |
| Cost of Equity | 6.51% |
| Cost of Debt | 5.00% |
| WACC | 6.40% |